Cedric Hermans and Glenn Pierce On The Essential Role of A Positive Reinvestment Cycle in Hemophilia
Cedric Hermans, Head of Haemophilia Centre at the Cliniques Universitaires Saint-Luc in Brussels, shared on LinkedIn:
”Hemophilia stands out among rare diseases for its remarkable therapeutic progress, a success built on decades of innovation, scientific discovery, and investment.
From the cloning of FVIII and FIX genes to the arrival of gene therapy, each milestone has transformed lives.
Global advocacy by WFH, EAHAD, and NBDF has been key to ensuring access and safety.
Yet, sustaining this progress requires continued commitment and investment, so that every person with hemophilia can benefit from the full promise of science.”
Read the full article here.
Article: Therapeutic innovations in hemophilia: the essential role of a positive reinvestment cycle
Authors: Cedric Hermans, Glenn F Pierce
Stay updated on all scientific advances in the field of hemophilia with Hemostasis Today.
-
Nov 8, 2025, 05:31Phenotyping of Human Platelets by Daisie Yates
-
Nov 8, 2025, 04:35Inaugural Women In Hematology US Focus Meeting 2025 Officially Commenced
-
Nov 7, 2025, 06:59Stephen Cornelissen is Celebrating an Extraordinary Milestone at Australian Red Cross Lifeblood
-
Nov 7, 2025, 06:56Reza Shojaei on Leadership in the Blood and Plasma Sector
-
Nov 7, 2025, 06:52Rachel Margolis-Goodman Announces Groundbreaking Expension of Versiti Blood Research Institute
-
Nov 7, 2025, 06:46What’s New in HIT from THANZ Webinar Series
-
Nov 7, 2025, 03:30Abdallah Othman About Cardiac Vasculature
-
Nov 7, 2025, 03:29Aabha Divya: Thrilled to Share Our Latest Publication in Annals of Thoracic Surgery Short Reports!
-
Nov 7, 2025, 03:28Shantel Holcomb: Boston Scientific is Investing in Innovative Solutions to Improve Outcomes for Patients With CAD